Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib with whole-brain radiotherapy for brain metastases from non-small cell lung cancer
ACTRN12612001245886Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of veliparib in non-small cell lung cancer (NSCLC) and brain metastases (3 arms), sponsored by AbbVie Inc. Primary endpoint: Overall survival. Started Sep 2012; status: recruiting.
02
Drugs
veliparib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ACTRN12612001245886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001245886.